Edwards Lifesciences Corp (NYSE:EW) CFO Sells $1,757,100.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) CFO Scott B. Ullem sold 7,500 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $234.28, for a total transaction of $1,757,100.00. Following the completion of the sale, the chief financial officer now directly owns 17,438 shares in the company, valued at approximately $4,085,374.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

EW stock opened at $239.35 on Wednesday. The company has a market cap of $48.84 billion, a P/E ratio of 50.93, a P/E/G ratio of 2.83 and a beta of 0.82. Edwards Lifesciences Corp has a 52 week low of $139.64 and a 52 week high of $241.82. The company’s 50-day moving average price is $227.79 and its 200 day moving average price is $204.18. The company has a current ratio of 3.53, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.19. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The firm’s revenue was up 20.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.07 earnings per share. On average, equities research analysts expect that Edwards Lifesciences Corp will post 5.6 earnings per share for the current year.

Several brokerages have recently weighed in on EW. ValuEngine downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America lifted their target price on shares of Edwards Lifesciences from $225.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 24th. Raymond James lifted their target price on shares of Edwards Lifesciences from $250.00 to $255.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $228.00 to $248.00 and gave the company an “overweight” rating in a report on Thursday, October 24th. Finally, Piper Jaffray Companies lifted their target price on shares of Edwards Lifesciences from $240.00 to $255.00 and gave the company an “overweight” rating in a report on Thursday, October 24th. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $237.89.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC raised its position in Edwards Lifesciences by 4.8% during the second quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock worth $1,115,646,000 after acquiring an additional 275,182 shares during the last quarter. Nuveen Asset Management LLC raised its position in Edwards Lifesciences by 8,278.5% during the second quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after acquiring an additional 3,904,405 shares during the last quarter. Northern Trust Corp raised its position in Edwards Lifesciences by 2.1% during the second quarter. Northern Trust Corp now owns 2,422,599 shares of the medical research company’s stock worth $447,551,000 after acquiring an additional 48,931 shares during the last quarter. Royal Bank of Canada raised its position in Edwards Lifesciences by 7.2% during the second quarter. Royal Bank of Canada now owns 1,650,840 shares of the medical research company’s stock worth $304,976,000 after acquiring an additional 110,497 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Edwards Lifesciences by 2.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,500,196 shares of the medical research company’s stock worth $329,908,000 after acquiring an additional 31,515 shares during the last quarter. Institutional investors own 80.53% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: Bond

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.